Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
CONCLUSIONS: Both abiraterone acetate and enzalutamide have toxicity profile characteristics that need to be recognized. Understanding the toxicity profile characteristics of both drugs could promote decision making in clinical use.
PMID: 29257709 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
More News: Abiraterone Acetate | Back Pain | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Hypertension | Liver | Pain | Prostate Cancer | Study | Toxicology | Urology & Nephrology